the 3rd cals annual symposium - scbasociety.org scba...gastroenterology, hepatology, nat...

1

肝病学分会 Hepatology Division

(北美华人肝病研究会CALS)

The 3rd CALS Annual Symposium

October 30-31, 2020Times are in EDT (GMT -4)

Oct 30: 6:00 pm-midnightOct 31: 9:00 am-5:00 pm

https://scbasociety.org/hepatology-division

1

Program

October 30, 2020

https://us02web.zoom.us/j/8200615783?pwd=UkY3OVpBb2xYTlp5MllNVzdHeEJHZz09

Meeting ID: 820 061 5783 Passcode: CALS2020

6:00-6:10 pm Welcome and opening remark

6:10-7:15 pm Session I Metabolic Liver Diseases

7:30-8:40 pm Session II Mechanisms of Liver Injury and

Regeneration

8:50-9:30 pm Keynote Lecture

9:35-10:40 pm Session III Parallel sessions for Liver Diseases

9:35 – 10:40 pm Parallel session I Fatty Liver Disease

https://zoom.us/j/8165673248?pwd=YU5HYlFieDFTTFc1bi9NZUxxSGo3QT09 Meeting ID: 816 567 3248 Passcode: CALS2020

9:35 – 10:40 pm Parallel session II ALD and Liver Injury



9:35 – 10:40 pm Parallel session III Hepatocellular Carcinoma

https://us02web.zoom.us/j/6074438562?pwd=aUpqckJHbFVRdjhhWDhhT2lRQnNEZz09


9:35 – 10:40 pm Parallel session IV Liver Fibrosis

https://us02web.zoom.us/j/7327686476?pwd=SzhCZnZUbTBDWlhQQ2t2bUFiTThtUT09 Meeting ID: 732 768 6476 Passcode: CALS2020


https://zoom.us/j/8165673248?pwd=YU5HYlFieDFTTFc1bi9NZUxxSGo3QT09



https://us02web.zoom.us/j/7327686476?pwd=SzhCZnZUbTBDWlhQQ2t2bUFiTThtUT09

2

10:45–12:00 am Session IV Parallel Poster Sessions

10:45 – 11:55 pm Poster session I Fatty Liver Disease


10:45 – 12:00 am Poster session II ALD and Liver Injury



10:45 – 12:00 am Poster session III Liver Carcinoma



10:45 – 11:55 pm Poster session IV Liver Fibrosis


October 31, 2020 https://us02web.zoom.us/j/8200615783?pwd=UkY3OVpBb2xYTlp5MllNVzdHeEJHZz09


9:00-10:00 am Session V Cholestatic and Autoimmune Liver

Diseases

10:00–11:00 am Session VI Gut-Liver Axis and Microbiome

11:15-12:15 pm Session VII Liver Cancer

1:00–2:10 pm Session VIII Novel and Improved Techniques in Liver

Research

2:10–2:30 pm Session IX Sponsor Presentation

3:10–4:00 pm Session X Award Presentation

4:00–5:00 pm Session XI Business Reports






Keynote Speaker

Dr. Lu is a physician-scientist engaged in teaching, clinical work, and basic science

research. Lu is originally from Taiwan, moved to the U.S. for undergraduate and medical

school at UCLA. This was followed by internal medicine residency at Cedars-Sinai and

gastroenterology fellowship at UCLA. She followed her mentor Neil Kaplowitz to USC

Keck School of Medicine, where she stayed for nearly 25 years before returning to

Cedars-Sinai as Director of the Division of Gastroenterology in August 2014.

Dr. Lu has been working in the fields of S-adenosylmethionine (SAMe) and glutathione

(GSH) metabolism for over 27 years and has received uninterrupted funding from the

National Institutes of Health (NIH) since 1992. She currently has five active NIH-funded

research programs that investigate molecular mechanisms and potential treatments of

alcoholic and non-alcoholic fatty liver disease (NAFLD), and liver cancer. Her research

encompasses basic mechanisms, translational implications, and clinical trial. Lu has

authored over 250 original papers, invited reviews and chapters, served as a standing

member of multiple NIH study sections, as Associate Editor of multiple journals including

GASTROENTEROLOGY and HEPATOLOGY, and received multiple awards including the

AGA Outstanding Women in Science Award and was inducted into honorary societies for

physician scientists such as the American Society for Clinical Investigation in 2002 and

the Association of American Physicians in 2006. She has mentored over 50 pre-doctoral

and postdoctoral trainees and over 20 junior faculties during her career. She was

recognized as an outstanding mentor with the Mayo Soley Award for Lifetime

Achievement in Science and Mentoring in 2012.

Shelly C. Lu, MD

Women's Guild Chair in

Gastroenterology

Director, the Karsh Division of

Gastroenterology and

Hepatology;

Professor of Medicine

Cedars-Sinai, UCLA

Invited Speakers

Heather Francis

(Indiana University School of Medicine) Dr. Francis is a professor of medicine at IU school of medicine and a VA Research Career Scientist at Richard L. Roudebush VA Medical Center in Indianapolis. Dr. Francis relocated from Texas A&M University in January of 2019 to join IU and has continued her work on cholangiocyte pathobiology and mast cell interactions during cholestatic liver injury and liver cancer. Currently Dr. Francis is funded by 2 NIH RO1 grants (NIDDK) and 1 VA Merit award and serves as the chairperson for the NIH Hepatobiliary pathophysiology study section through 2022. The goal of heather’s lab is to investigate the synergistic role that cholangiocytes and mast cells play during cholestatic liver injury, cholangiocarcinoma and non-alcoholic fatty liver disease (NAFLD). She is particularly interested in the HDC/histamine/HR

axis and the autocrine (from cholangiocytes) and paracrine (mast cells) role this axis plays in primary sclerosing cholangitis, primary biliary cholangitis, cholangiocarcinoma and NAFLD. Using genetic knockout mice, Dr. Francis has demonstrated that loss of HDC and/or loss of mast cell activation ameliorates liver damage including biliary hyperplasia and hepatic fibrosis. Mast cells also play a role in cholangiocarcinoma tumorigenesis, angiogenesis and epithelial mesenchymal transition (EMT). She has found that inhibition of mast cell-derived histamine using cromolyn sodium decreases these features of cholangiocarcinoma progression. Her work is clinically relevant and topical as demonstrated by the numerous presentations she’s given both at national and international meetings and conferences. Today Dr. Francis will present work on the role of mast cells and cholangiocytes during cholestatic liver injury and cholangiocarcinoma.

Gen-Sheng Feng (UCSD)

Dr. Feng received his college education from Hangzhou University (now

Zhejiang University), and his MSc degree in Immunology from the 2nd Army

Medical University in Shanghai. He then did his PhD thesis work in Indiana University Bloomington, and postdoctoral work at University of Toronto, supported by a Canadian MRC fellowship. He is now a professor in the Department of Pathology and the Division of Biological Sciences, University of California San Diego. His research program aims at understanding the dynamic interplay between signaling pathways in different cell types in health and disease. This work was initiated by discovery of an SH2-containing tyrosine phosphatase Shp2 (originally called Syp) as a postdoc in Pawson’s lab (Feng et al., Science, 1993). Shp2 has now become a very

hot drug target in oncological treatment in the pharmaceutical industry worldwide. The current focus of Feng lab is on elucidating the anti-oncogenic effects of pro-oncogenic molecules in liver cancer, identified most recently by his and other labs. This work has revealed previously unrecognized complex mechanisms of liver tumorigenesis. His group demonstrated that disrupting oncogenic signaling pathways in tumor cells generates a tumor-promoting microenvironment in the liver, which can accelerate growth of relapsed tumors after the primary treatment. Feng and his colleagues have established a math model and a new concept of tumorigenic index (TI) for quantitative determination of tumorigenic signal strengths, tumor stages and prognosis. Their most recent data provide a proof of principle for a combination immunotherapy of HCC by coordinated activation of innate and adaptive immunity. Feng currently serves on the editorial boards of Hepatology, Journal of Hepatology, MCB and Molecular Cancer Research. Feng is one of co-organizers for Cold Spring Harbor- Asia conference on liver biology, diseases and cancer in Japan (2019), and FASEB liver research conference in 2020.

Yong He (NIH/NIAAA) Dr. He received his M.S from Anhui Medical university, China, in 2013 and his Ph.D. in 2016 by attending Graduate Partnership Program (GPP) between Anhui Medical University, China and National Institutes of Health (NIH), USA in 2014. Following 3 years postdoctoral training in Dr. Bin Gao’s lab in the Laboratory of liver diseases at National Institute on Alcohol Abuse and Alcoholism (NIAAA)/NIH, he pursued his Research Fellowship at NIAAA/NIH in 2019. Since joining the NIAAA in 2014, Dr. He received FARE (Fellows Award for Research Excellence) 2016/2017/2020 Award. In the past several years, Dr. He has been actively investigating the immunological aspects and molecular pathogenesis of liver diseases including nonalcoholic steatohepatitis (NASH), acute liver injury, alcoholic liver disease, and

hepatocellular carcinoma (HCC), focusing on the roles of extracellular vesicles (EVs), miRNAs (neutrophil-specific miR-223) and cytokines (IL-20 family) in the progression of liver diseases. Dr. He has published more than 28 peer-reviewed publications in the highly prestigious journals including Gut, Hepatology, Journal of Hepatology, Journal of Clinical Investigation, and Cancer letters. Dr. He was also selected for oral or poster presentation in many major national and international conferences.

Yasuko Iwakiri (Yale University) Dr. Iwakiri is an Associate Professor of Medicine in the Section of Digestive Diseases at Yale School of Medicine, conducting basic and translational research in various liver diseases with particular interest in liver fibrosis, portal hypertension and lymphatic vascular systems. After receiving her PhD degree in nutritional biochemistry from Colorado State University, she moved to Yale University for her postdoctoral training and then promoted to the faculty position. She has been actively involved in multiple AASLD committees, including abstract review committees, the Basic Research Committee, Research Award Committee and currently Chair of Liver Cell Biology in Hepatic Diseases Single Interest Group. She served as an Associate Editor for the Hepatology Elsewhere section of Hepatology from

2011 to 2016 and have also served as an editorial board member on major Hepatology journals including Journal of Hepatology, Hepatology International, Liver International, Liver Research and JHEP Reports. She was a standing member of the Biomedical Research Review Subcommittee (AA-1) at NIH/NIAAA from 2016 to 2020.

Invited Speakers

Jong-Min Jeong

(Department of Anesthesiology, McGovern Medical School, University of Texas Health Science Center at Houston, Houston) I am a post-doc in Dr. Cynthia Ju’s Lab, UT medical school. We are now exploring the roles of hepatic immune cells in acute and chronic liver damage. I am interested in the hepatic microenvironment during liver injury, especially in interaction with hepatic parenchyma and non-parenchyma cells.

Feng Li (Baylor College of Medicine) Dr. Feng Li’s work focuses on drug metabolism and mechanistic studies of drug-induced liver injury (DILI). The strategy of integrating transgenic animal models (e.g., Por-null mice, PXR-humanized mice) and LC-MS-based metabolomics approaches are commonly employed in these studies. He received his PhD degrees from the University of Stuttgart, Germany and completed a postdoctoral fellowship at National Institute of Heaths (NIH) and the University of Kansas Medical Center. He is currently an Assistant Professor in the Departments of Pathology & Immunology and Pharmacology & Chemical Biology, Baylor College of Medicine, where his research centers on mechanism of DILI associated with antidepressants and pharmacokinetics. He has published 66 co-author

papers including Nature Medicine, Nature Communications, Biochemical Pharmacology, Drug Metabolism and Disposition, European Journal of Pharmaceutical Sciences, etc. on peer reviewed reputed journals.

Invited Speakers

Liangyou Rui (University of Michigan Medical School) I obtained my BS from the Each China Normal University (Shanghai, China), MS from the Peking Union Medical College/Chinese Academy of Medical Sciences (Beijing, China), and Ph.D. (with Dr. Christin Carter-Su) from the University of Michigan Medical School (Michigan, USA). I completed my postdoctoral training with Dr. Morris F. White at the Joslin Diabetes Center, Harvard University (Boston, USA). I have conducted my independent research programs as an assistant, associate, and full professor in the Department of Molecular and Integrative Physiology, University of Michigan Medical School, Ann Arbor, Michigan, since 2002. My research is centered on obesity and obesity-associated diseases, including liver disease. We are

particularly interested in crosstalk between liver and fat, and between brain and liver, in the settings of alcoholic and nonalcoholic liver diseases. My team has delineated physiological and pathogenic actions of several genes, including Sh2b1, NIK, Lcn13, Traf2/3, Snail1, and Slug, in the hypothalamus, liver, and/or fat.

Lichun Ma

(National Cancer Institute) Dr. Ma received a Bachelor’s degree in Electronic Information Science and Technology from Xidian University in 2010, a Master’s degree in Signal Processing from Chinese Academia of Sciences in 2013, and a Ph.D. degree in Electronic Engineering at City University of Hong Kong in 2016. During her Ph.D., Dr. Ma was studying protein structure modeling under the supervision of Prof. Hong Yan who is pioneering in biomedical image processing using machine learning. She was then awarded a one-year postdoctoral fellowship at Nanyang Technological University, Singapore, studying gene regulatory networks and signaling pathways in ageing-related diseases using mathematical modeling. In 2017, Dr. Ma joined National Cancer Institute (NCI) where she initiated

her research in cancer biology using single-cell techniques as a part of Liver Cancer Moonshoot. She has strong background of mathematics, information theory, machine learning and computer programming. Dr. Ma was recipients of National Scholarship and Postgraduate National Scholarship of China. She was also recipients of highly competitive Outstanding Academic Performance Award and Research Tuition Scholarship of City University of Hong Kong. In addition, she received the Fellows Award for Research Excellence of NIH and Keystone Symposia Future of Science Fund scholarship, both of which were highly competitive. She has published over 20 research articles in peer-reviewed journals, such as Cancer Cell, Hepatology, BMC Systems Biology, BMC Bioinformatics, etc. Her recent outstanding work of tumor cell biodiversity and microenvironmental reprogramming in liver cancer was selected as top 1% of all published studies in 2019 to be showcased in the 2019-2020 Center for Cancer Research of NCI Milestones publication. She was recently invited as a speaker to present her work at the AACR Conference of Tumor Heterogeneity: From Single Cells to Clinical Impact in 2020. Dr. Ma’s main research interest is on understanding tumor cell heterogeneity and tumor evolution.

Invited Speakers

Hongbing Wang

(Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy) Dr. Hongbing Wang, Professor & Program Chair, Experimental and Translational Therapeutics, Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy. Dr. Wang has a long-standing interest in studying the function and regulation of xenobiotic-metabolizing enzymes and drug transporters in human liver. Specific research focus has been centered on: 1) the molecular mechanisms of nuclear receptors, such as pregnane X receptor (PXR)- and constitutive androstane receptor (CAR)-mediated transcriptional regulation of drug-metabolizing genes in human liver; 2) pharmacokinetic-based drug-drug and herbal-drug interactions; 3) human CAR as a novel therapeutic target of metabolic

disorders and cancers; 4) the role of bile salt export pump (BSEP) in drug-induced cholestasis; 5) the function and regulation of SLC13A5 in energy homeostasis and cell proliferation; and 6) CYP enzymes in alcohol metabolism and alcoholic liver damage. These research projects include aspects of cell biology, molecular biology, toxicology, and metabolism while utilizing models from 2D- 3D-culture of human primary hepatocytes, non-parenchymal liver cells, cancer cell lines, to transgenic animal models. Over the years, Dr. Wang’s research has been continuously sponsored by NIH and other research grants. He has published more than 90 research articles and has severed as a reviewer for many research funding agencies and peer-reviewed journals.

Xudong Wu

(Nanjing University) Dr. Wu has been working at the School of Life Sciences of Nanjing University as a full professor since 2018. Dr. Wu’s current researches are focused on metabolic syndrome and inflammation. Dr. Wu’s research is aimed to identify the new mechanism, and look for novel therapeutic drugs. And till now, Dr. Wu has published several representative papers in high impact journals, such as Gastroenterology, Hepatology, Nat Communications, Redox Biology, British Journal of Pharmacology, et al. Now Dr. Wu serves on the editorial board member of Chinese Journal of Natural Medicines and peer reviewer for Biochemical Pharmacology, International Journal of Biological Macromolecules, International

Journal of Immunopharmacology, et al.

Invited Speakers

Xiaogang Xiang (Shanghai Ruijin Hospital, Shanghai Jiao Tong University School of Medicine) Dr. Xiang is an associate professor of Department of Infectious Diseases, Shanghai Ruijin hospital, Shanghai Jiao Tong University. He is a physician major in liver and infectious diseases. He received his PhD degree at Shanghai Jiao Tong University School of Medicine. During 2017 to 2019, he was a visiting fellow in NIH/NIAAA in Professor Bin Gao’ lab working on acute-on-chronic liver failure (ACLF).

Shengmin Yan (Tulane University School of Medicine) Dr. Shengmin Yan received his doctoral degree at the Institute of Zoology, Chinese Academy of Sciences, graduating in 2015. His doctoral thesis focused on the mechanistic discoveries of hepatotoxicity of perfluorooctanoic acid (PFOA). Dr. Yan’s postdoctoral work was carried out in Dr. Xiao-Ming Yin’s laboratory at Indiana University School of medicine. His postdoctoral work has extended his expertise in hepatotoxicity to autophagy related liver dysfunction and fatty liver diseases. By using multiple different mouse strains, he tested the impact of hepatic autophagy deficiency on alcohol-related liver diseases, and the impact of gut microbiota on diet-induced obesity and autophagy deficiency-induced liver injury. In 2020, Dr. Yan was appointed as an Instructor at

Tulane University School of Medicine. Dr. Yan has a broad background in liver diseases, with specific training and expertise in hepatotoxicity, fatty liver diseases, gut-liver interaction, and laboratory medicine. His research includes basic and translational research in obesity, non-alcoholic fatty liver diseases, alcoholic fatty liver diseases, drug-induced liver injury, and environmental hepatotoxicity. Dr. Yan’s current research interests include 1) the role of autophagy in liver pathophysiology and 2) the impact of immunometabolism in the progression of NAFLD/NASH.

Invited Speakers

Ling Yang (Division of Gastroenterology, Department of Internal Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology) Dr.Yang is an expert in the clinical management and basic research of chronic liver diseases in the Division of Gastroenterology, Department of Internal Medicine, Union Hospital, Huazhong University of Science&Technology. From 2010 to 2013 she served as a visiting associated professor in the Department of Gastroenterology, University of California, San Diego. She has published in such highly-regarded journals as Gastroenterology, Hepatology, Journal of Clinical Investigation, J Hepatology and she has authored multiple reviews and book chapters. Dr. Yang serves as the Youth Committee of the Chinese Society of Gastroenterology (CSG), associated chair of Wuhan

Academic Committee of the Digestive Diseases of integrated traditional and western medicine, committee of the Hepatobilliary Diseases Group, the Gut Microbiota Group and the Integrated traditional and Western medicine group of CSG. She is also the member of the American Gastroenterological Association(AGA) and the American Association for the Study of Liver Diseases(AASLD). Her many honors include Postdoctoral Research Fellowship Awards from China Postdoctoral Science Foundation and Huazhong University of Science&Technology, Science & Technology Progress Awards from the Hubei Province Government. Dr.Yang is the Principal Investigator for National Natural Science Foundation of China(NSFC,2014-2023). Currently Dr. Yang’s research focuses on understanding the molecular pathogenesis and intervention of the chronic liver diseases, intestinal microbiome and metabolites associated with the progress of liver diseases, the prevention of liver fibrosis, NASH and HCC.

Linkang Zhou (University of Michigan) Through my graduate and post-doc training at Tsinghua University, Beijing, I acquired a broad range of knowledge and hand-on skills in cellular metabolism and mouse physiology. I found that both Cidea and Cidec were dramatically increased in steatosis hepatocytes. My findings suggest that in the context of surplus energy intake, Cidec deficiency can switch a relatively “lean and healthy” insulin-sensitive animal to a “lipodystrophic” insulin-resistant state. I characterized the coordination among LDs, peroxisomes, and mitochondria could regulate energy expenditure through the CIDE- ATGL- PPARα pathway. I have made significant contributions to the understanding of lipid metabolism in adipose tissue and liver, from molecular mechanisms and pathophysiology. Specifically, I elucidated the

role of CIDE proteins in the dynamic regulation of lipid droplet fusion. To broaden my skills and familiarity with other research environments, in 2018, I joined Dr. Jiandie Lin’s lab at the University of Michigan as a postdoctoral fellow, focusing on cell-cell crosstalk. My first year of research experience improved my scientific thinking and communication effectively, and I was promoted to Research Investigator in September 2019. In my new position, I will continue to combine my skills to establish a multidisciplinary research project to study how tissue-resident macrophages affect liver NASH development and metabolic syndromes.

Invited Speakers

1

The 3rd CALS Annual Symposium

October 30-31, 2020

Times are in EDT (GMT -4)

Online Zoom Meeting



Final Program

October 30, 2020

6:00-6:10 pm Welcome and opening remark Huiping Zhou (Virginia Commonwealth University)

6:10-7:15 pm Session I Metabolic Liver Diseases Moderators: Mengwei Zang (University of Texas Health San Antonio)

Shengmin Yan (Tulane University)

6:15 - 6:30 pm Liangyou Rui, University of Michigan

“Tissue crosstalk and metabolic liver disease.”

6:30 - 6:45 pm Linkang Zhou, University of Michigan

“Elucidating the regulation and pathophysiological role of NASH-

associated macrophages”

6:45 - 6:55 pm Seonghwan Hwang, NIAAA, NIH

“Overexpression of CXCL1/IL-8 promotes the progression from

steatosis to NASH in high-fat diet-fed mice: a new model of NASH.”

肝病学分会 Hepatology Division

(北美华人肝病研究会 CALS)


2

6:55 - 7:05 pm Chaodong Wu, Texas A&M University

“Differential roles for PFKFB3 in regulating hepatic steatosis and

inflammation in cell type-dependent manners”

7:05 - 7:15 pm Xiaoxiao Jiang, University of Kansas Medical Center

“Role of VMP1 in Regulation of Hepatic Lipid Metabolism”

7:30-8:40 pm Session II Mechanisms of Liver Injury and

Regeneration Moderators: Zhaoli Sun (John Hopkins University),

Dechun Feng (NIAAA)

7:35 - 7:50 pm Yasuko Iwakiri, Yale University

“The role of lymphatic vessels in the liver.”

7:50 - 8:05 pm Xiaogang Xiang, Shanghai Jiaotong University

“Acute on chronic liver injury and regeneration.”

8:05 - 8:15 pm Sandie Zhao, Yunnan University

“Chitinase 3-like-1 Contributes to Acute Liver Injury and Serves as a

Therapeutic Target”

8:15 - 8:25 pm Shicheng Fan, Sun Yat-Sen University

“Peroxisome proliferator-activated receptor α promotes hepatomegaly

and liver regeneration via yes-associated protein activation in mice.”

8:25 - 8:35 pm Dong Xiang, Huazhong University of Science and Technology

“Association of ACE2, inflammatory cytokines, and antiviral-drugs

with abnormal liver function in patients with hypertension hospitalized

for COVID-19.”

8:35 - 8:50 pm Break

8:50-9:30 pm Keynote Lecture Moderator: Xinwei Wang (NIH/NCI)

Speaker: Shelly Lu, Cedars-Sinai Medical Center

“Methionine adenosyltransferases in liver cancer”

3

9:35-10:40 pm Session III Parallel sessions for Liver Diseases

9:35 – 10:40 pm Parallel session I Fatty Liver Disease

Moderators: Yanqiao Zhang (NEOMED)

Xinwen Wang (NEOMED)


9:35 – 9:40 pm Robim M Rodrigues, NIAAA, NIH

“E-selectin-dependent neutrophil recruitment in adipose tissue

exacerbates steatosis to NASH progression.”

9:40 – 9:45 pm Tian Lan, Guangdong Pharmaceutical University

“Liver-Specific Deficiency of Sphingosine Kinase 2 Promotes

Hepatic Steatosis in Nonalcoholic Fatty Liver Disease”

9:45 – 9:50 pm Xiaolin Wang, NIAAA, NIH

“Hepatic p38MAPK plays different roles in different stages of

NAFLD”

9:50 – 9:55 pm Yanyong Xu, Northeast Ohio Medical University

“Hepatocyte ATF3 protects against diet-induced nonalcoholic fatty

liver disease by regulating the HNF4α and bile acid signaling.”

9:55 – 10:00 pm Yanyan Wang, Virginia Commonwealth University

“HuR plays an Essential Role in Modulating Metabolic Stress and

Inflammation in the Liver”

10:00 – 10:05 pm Xiaohong Liang, Basic Medicine School of Shandong University

“TIPE1 is involved in NAFLD by sensing fatty acids and regulating

mTOR signaling pathway.”

10:05 – 10:40 pm Q & A


4

9:35 – 10:40 pm Parallel session II ALD and Liver Injury

Moderators: Pei Wang (University of Texas Health San Antonio)

Joe Yang (Indiana University)



9:35 – 9:40 pm Seol Hee Park, NIAAA, NIH

“Adipocyte death promotes alcoholic liver disease progression by

inducing endoplasmic reticulum stress.”

9:40 – 9:45 pm Zhihong Yang, Indiana University School of Medicine

“A novel mechanism of nuclear receptor REV-ERBα in the

pathogenesis of the alcohol-associated liver disease.”

9:45 – 9:50 pm Nan Wu, Indiana University School of Medicine

“Roles of hepatic stellate cells in NF-κB-induced inflammatory

signaling during alcohol-associated liver injury.”

9:50 – 9:55 pm Mengwei Jiang, University of Louisville School of Medicine

“Suppression of intestinal microRNA194 reduces hepatic bile acid

synthesis and liver injury in alcohol-fed mice through regulating

intestinal FXR-FGF15-mediated pathway.”

9:55 – 10:00 pm Xiaowen Ma, University of Kansas Medical Center

“Dynamic changes of mitochondrial morphology and mitophagy

independent of Parkin and Atg5 in cultured mouse hepatocytes.”

10:00 – 10:05 pm David Matye, University of Oklahoma Health Sciences Center

“Bile acid signaling antagonism improves insulin sensitivity through a

hepatic sulfur amino acid restriction-mimicking effect.”

10:05 – 10:10 pm Lindsey Kennedy, Indiana University School of Medicine

“Mast cell infiltration and activation promotes biliary MHC expression,

immune response and subsequent liver damage during late-stage

primary biliary cholangitis.”

10:10 – 10:40 pm Q & A


5

9:35 – 10:40 pm Parallel session III Hepatocellular Carcinoma

Moderators: Wen Xue (University of Massachusetts)

Xiao-Ming Yin (Tulane University)



9:35 – 9:40 pm Wonhyo Seo, NIAAA, NIH

“Aldehyde dehydrogenase 2 suppresses cirrhosis and alcohol-

induced hepatocellular carcinoma via the inhibition of acetaldehyde-

derived DNA damage and multiple oncogenic signaling pathways.”

9:40 – 9:45 pm Ningning Liu, University of Minnesota

“MicroRNA-206 Prevents Immunosuppression By Impairing

Activation and Enrichment of Regulatory T Cells in c-Myc and

AKT/Ras mice.”

9:45 – 9:50 pm Konstantina Kyritsi, Indiana University School of Medicine

“Crosstalk signaling between mast cells, histamine, and stimulator of

interferon gene (Sting/Tmem173) promotes cholangiocarcinoma

(CCA) tumorigenesis”

9:50 – 9:55 pm Tingting Jiang, University of Massachusetts Medical School

“Targeting de novo purine synthesis pathway via ADSL depletion

impairs liver cancer growth by perturbing mitochondrial function.”

9:55 – 10:00 pm Priyanka Ghosh, University of Kansas Medical Center

“Small molecule disrupting interactions between RNA-binding protein

HuR and glycolytic enzymes induce metabolic stress in human

hepatocellular carcinoma”

10:00 – 10:05 pm Ai-Ming Yu, University of California, Davis

“Bioengineering of novel RNA molecules to dissect HCC cell

metabolism”

10:05 – 10:10 pm Hua Su, University of California San Diego

“Macropinocytosis promotes fibrosis-supported primary and

metastatic cancer progression in the liver.”

10:10 – 10:40 pm Q & A


6

9:35 – 10:40 pm Parallel session IV Liver Fibrosis

Moderators: Charlie Dong (Indiana University)

Bingning Dong (Baylor College of Medicine)


9:35 – 9:40 pm Yuan Zhang, Virginia Commonwealth University

“MicroRNA 155-mediated upregulation of SREBP1 promotes

cholestatic liver injury under metabolic stress in Mdr2-/- mice.”

9:40 – 9:45 pm Yunling Tai, Virginia Commonwealth University

“Hepatic deficiency of sphingosine Kinase 2 exacerbates bile duct

ligation-induced cholestatic liver injury.”

9:45 – 9:50 pm Tianhao Zhou, Indiana University School of Medicine

“MicroRNA-Mediated Macrophage Polarization and its Potential Role

in the Regulation of Ductular Reaction during Cholestatic Liver

Injury”

9:50 – 9:55 pm Wenquan Hu, New York University, Long Island School of Medicine

“Nogo-B receptor deficiency in hepatocytes increases hepatic

lipogenesis and insulin resistance through LKB1-AMPKa-dependent

pathway”

9:55 – 10:00 pm Vik Meadows, Indiana University School of Medicine

“Mast cell activation, ductular reaction and hepatic fibrosis decrease

following inhibition of biliary ASBT via Vivo-Morpholino treatment in

Mdr2-/- mice.”

10:00 – 10:05 pm Debjyoti Kundu, Indiana University School of Medicine

“Senescence Associated Secretory Phenotype (SASP) and Biliary

Senescence are Affected by Bile Acid Feeding Via Mast Cell

Activation in a Cholestatic model.”

10:05 – 10:10 pm Liu Ying Chen, Huazhong University of Science and Technology

“Liver damage at admission is an independent prognostic factor for

COVID-19”

10:10 – 10:40 pm Q & A


7

10:45–12:00 am Session IV Parallel Poster Sessions

10:45 – 11:55 pm Poster session I Fatty Liver Disease

Moderators: Liqing Yu (University of Maryland)

Ling Yang (University of Iowa)


10:45 – 10:50 pm Hyeong-Geug Kim, Indiana University School of Medicine

“Sestrin proteins protect against hepatic lipotoxicity through inhibition

of the JNK stress kinase”

10:50 – 10:55 pm Yong He, NIAAA, NIH

“Interleukin-20 exacerbates acute hepatitis and bacterial infection by

downregulating IκBζ target genes in hepatocytes.”

10:55 – 11:00 pm Mary Stofan, Rutgers University

“FGF15 Overexpression is Protective Against Diet-Induced NASH in

Mice”

11:00 – 11:05 pm Xiaoyue Pan, NYU Winthrop Hospital

“Deregulation of Clock, Hif1α and CD36 in the onset of liver

diseases”

11:05 – 11:10 pm Xue Lanfeng, Nanhai Hospital of Southern Medical University

“Clinical study on the treatment of nonalcoholic fatty liver disease

with fecal microbiota transplantation.”

11:10 – 11:15 pm Alexandra Griffiths, University of Illinois at Chicago

“Inositol requiring enzyme 1 alpha (IRE1a) links palmitate-induced

mTOR activation and lipotoxicity in Hepatocytes.”

11:15 – 11:20 pm Lixiao Che, University of Cincinnati College of Medicine

“Hepatocellular DNA damage and cell death in NASH.”

11:20 – 11:25 pm Lili Ding, City of Hope National Medical Center

“Vertical sleeve gastrectomy confers metabolic improvements by

reducing intestinal bile acids and lipid absorption in mice.”

11:25 – 11:55 pm Q & A


8

10:45 – 12:00 am Poster session II ALD and Liver Injury

Moderators: Wenke Feng (University of Louisville)

Dechun Feng (NIAAA)



10:45 – 10:50 pm Zhi Zhong, Medical University of South Carolina

“Mitochondrial depolarization drives Type 2 mitophagy after acute

ethanol treatment.”

10:50 – 10:55 pm Yang Yang, University of Texas HSC at Houston

“Eosinophils attenuate hepatic ischemia-reperfusion injury through

ST2-dependent IL-13 production.”

10:55 – 11:00 pm Yang Sun, Shandong University

“Linc01431 promotes histone H4 methylation on HBV cccDNA to

impede HBV transcription by stabilizing PRMT1.”

11:00 – 11:05 pm Zhuanchang Wu, Shandong University

“Mapping cccDNA-host interactome identifies cohesin complex as a

novel HBV restriction factor”

11:05 – 11:10 pm Yilin Yang, Yale School of Medicine

“Alcohol-driven Hsp90 acetylation leads to liver sinusoidal endothelial

cell dysfunction and alcoholic liver disease”

11:10 – 11:15 pm Yue Gao, Sun Yat-Sen University

“Constitutive androstane receptor activation-induced hepatomegaly

and liver regeneration is partially via yes-associated protein”

11:15 – 11:20 pm Pengfei Xu, University of Pittsburgh

“Sulfoconjugation of p53 dictates oxidative liver injury via the p53-

p21-Nrf2 axis”

11:20 – 11:25 pm Yifan Bao, University of Connecticut

“Alterations of drug metabolism and therapeutic efficacy during liver

recovery and regeneration after acetaminophen-induced liver injury”

11:25 – 11:30 pm Liyuan Wang, Shandong University

“Hepatitis B virus evades immune recognition via adenosine

deaminases acting on RNA mediated viral RNA editing.”

11:30 – 12:00 am Q & A


9

10:45 – 12:00 am Poster session III Liver Carcinoma

Moderators: Wendong Huang (City of Hope)

Lisa Zhang (KUMC)



10:45 – 10:50 pm Wen-Ming Chu, University of Hawaii

“The EGFR-binding long noncoding RNA lnc-EGFR connects Treg

cells to hepatocellular carcinoma.”

10:50 – 10:55 pm Wanshui Yang, Harvard Medical School

“Association of Inflammatory and Insulinemic Potential of Diet and

Lifestyle with Risk of Hepatocellular Carcinoma”

10:55 – 11:00 pm Yaojie Fu, NIAAA, NIH

“VPAC1 mediated signaling inhibits tumor progression and is a

potential therapeutical target for hepatocellular carcinoma.”

11:00 – 11:05 pm Taojian Tu, University of Southern California

“Role of CXCL5 in HCC Tumorigenesis”

11:05 – 11:10 pm Hao Wang, Loyola University Chicago

“EphA2 promotes HCC development by regulation of JAK1/STAT3

and AKT signaling.”

11:10 – 11:15 pm Meiyi Song, Tongji University School of Medicine

“CITED4 suppression inhibits hepatocellular carcinoma.”

11:15 – 11:20 pm J Candia, NCI, NIH

“The genomic landscape of Mongolian hepatocellular carcinoma.”

11:20 – 11:25 pm Katsuya Nagaoka, Brown University

“Aspartate beta-hydroxylase modulates chemoresistance of

cholangiocarcinoma by targeting ATM and ATR”

11:25 – 11:30 pm Xuewei Bai, Brown University

“The 2-oxoglutarate dioxygenase, TET1 promotes the malignant

progression of cholangiocarcinoma with wild-type IDH1 through

epigenetic control.”

11:30 – 12:00 am Q & A


10

10:45 – 11:55 pm Poster session IV Liver Fibrosis

Moderators: Grace Guo (Rutgers University)

Chaodong Wu (Texas A&M University)


10:45 – 10:50 pm Daniel Rizzolo, Rutgers University

“Sexual dimorphism of bile acid homeostasis in mice deficient in

Cyp7a1 and Cyp27a1.”

10:50 – 10:55 pm Ludovica Ceci, Indiana University School of Medicine

“Prolonged administration of melatonin to the Mdr2 mouse model of

primary sclerosis cholangitis (PSC) decreases inflammation and

oxidative stress through the restoration of the circadian rhythm.”

10:55 – 11:00 pm Nan Wu, Indiana University School of Medicine

“Effects of MT1 and MT2 melatonin receptor deletion on ductular

reaction, biliary senescence and fibrosis in liver cholestasis.”

11:00 – 11:05 pm Tianhao Zhou, Indiana University School of Medicine

“Biliary mtDNA promotes STING activation and liver fibrosis in the

Mdr2-/- mouse model of primary sclerosing cholangitis (PSC)”

11:05 – 11:10 pm Lixian Chen, Indiana University School of Medicine

“Treatment with melatonin or dark therapy decreases mast cell (MC)

activation by downregulation of miR-200b-dependent histamine (HA)

signaling in Mdr2 mice: A novel scenario for PSC management.”

11:10 – 11:15 pm Shao-Jung Hsu, Yale School of Medicine

“Enhanced meningeal lymphatic drainage ameliorates

neuroinflammation and hepatic encephalopathy in cirrhotic rats.”

11:15 – 11:20 pm Na Chang, Capital Medical University

“Neutrophil-produced S100A8/A9 mediates mouse liver fibrogenesis

by inducing bone marrow-derived mesenchymal stromal cell homing.”

11:20 – 11:25 pm Ningning Liu, University of Minnesota

“MicroRNA-206 Promotes Recruitment of Effector T Cells by Driving

M1 Phase Polarization of Kupffer Cells”

11:25 – 11:55 am Q & A


11

October 31, 2020 https://us02web.zoom.us/j/8200615783?pwd=UkY3OVpBb2xYTlp5MllNVzdHeEJHZz09


9:00-10:00 am Session V Cholestatic and Autoimmune Liver

Diseases

Moderators: Lindsey Kennedy, Indiana University

Junkai Yan, Shanghai Institute of Pediatric Research

9:00 - 9:15 am Heather Francis, Indiana University

“The relationship between mast cells and cholangiocytes during liver

Injury: it’s complicated.”

9:15 - 9:30 am Xudong Wu, Nanjing University

“Annexin A5 selectively regulates hepatic macrophage polarization

via targeting PKM2 in NASH treatment”

9:30 - 9:40 am Junkai Yan, Shanghai Institute of Pediatric Research

“Sphingosine-1 phosphate receptor 2-induced Lin28a promotes

ductular reaction in cholestatic liver diseases.”

9:40 - 9:50 am Keisaku Sato, Indiana University

“Cholangiocyte-derived extracellular vesicles regulate fibrogenesis

and Epithelial-Mesenchymal transition of hepatic stellate cells during

cholestatic liver injury.”

9:50 - 10:00 am Xiaojuan Chao, University of Kansas Medical Center

“Chronic plus acute binge alcohol induces steatohepatitis and fibrosis

in mice with Hepatic Deficiency of Tuberous Sclerosis 1”

10:00–11:00 am Session VI Gut-Liver Axis and Microbiome

Moderators: Yu-Jui Yvonne Wan (UC Davis)

Tiangang Li (OUHSC)

10:00 – 10:15 am Ling Yang, Huazhong University of Science and Technology

“Microbiome in liver fibrosis.”

10:15 – 10:30 am Shenming Yan, Tulane University

“Microbiome and cholestatic liver disease.”


12

10:30 – 10:40 am Jinfang Zhao, Huazhong University of Science and Technology

“Hepatocyte-specific deleted TGF-β receptor 2 promotes white

adipose tissue browning in NAFLD mice induced by high-fat diet.”

10:40 – 10:50 am Ming Yang, University of Missouri-Columbia

“Gut microbiota impacts liver fibrosis by regulating hepatic immunity

and inflammation”

10:50 – 11:00 am Peng Chen, Southern Medical University, China

“The gut microbial metabolite, 3,4-dihydroxyphenylpropionic acid,

alleviates hepatic ischemia/reperfusion injury via mitigation of

macrophage pro-inflammatory activity in mice.”

11:00 – 11:15 am Break

11:15-12:15 pm Session VII Liver Cancer

Moderators: Ruth Aiwu He (Georgetown University)

Wei Qiu (Loyola University)

11:15 – 11:30 am Gengshen Feng, University of California at San Diego

“Double-edge sword oncogenes in HCC.”

11:30 – 11:45 am Yong He, NIH/NIAAA

“Neutrophil-specific miRNA 223: a gatekeeper for NASH

progression and liver cancer development.”

11:45 – 11:55 am Dan Li, NCI, National Institutes of Health, Bethesda

“GPC3-targeted chimeric antigen receptor (CAR) T cells eliminate

liver cancer in mice.”

11:55 – 12:05 pm Wei Fan, Cedars-Sinai Medical Center

“Prohibitin 1 and Methionine Adenosyltransferase α1 Cooperate to

Suppress Human Liver Cancer Cells Metastasis by Inhibiting Matrix

Metalloproteinase-7 Expression”

12:05 – 12:15 pm Yuchen Liu, Harvard School of Dental Medicine

“Sox9 is required to regulate Yap-induced hepatocyte plasticity in

mouse liver tumor”

12:15 - 1:00 pm Lunch Break

13

1:00–2:10 pm Session VIII Novel and Improved Techniques in Liver

Research

Moderators: Cynthia Ju (UT Houston)

Xiaobo Zhong (University of Connecticut)

1:00 – 1:15 pm Lichun Ma, NIH

“Single cell analysis.”

1:15 – 1:30 pm Jongmin Jeong, University of Texas at Houston

“NPC isolation.”

1:30 – 1:45 pm Hongbin Wang, University of Maryland

“Human liver organoid culture.”

1:45 – 2:00 pm Feng Li, Baylor College of Medicine

“Metabolomics oriented endogenous pathways in the study of drug-

induced liver injury.”

2:10–2:30 pm Session IX Sponsor Presentation

2:10 - 2:30 pm Liver Research

2:30 - 2:50 pm Dr. Xiaodan Wang, Biocytogen

“Genome Editing in Accelerating Discovery and Preclinical

Applications.”

2:50 – 3:10 pm Dr. Sridhar Radhakrishnan, Research Diets

3:10–4:00 pm Session X Award Presentation Moderator: Huiping Zhou, Bin Gao, Xiaoming Yin, Xinwei Wang

4:00–5:00 pm Session XI Business Reports

Moderator: Huiping Zhou

Treasurer’s report, Wen-Xing Ding

Secretary’s report, Yanqiao Zhang

Introduction of the next President: Huiping Zhou

We would like to thank all thesponsors and CALS members for theirgenerous support to our society andyoung generation of liver researchscientists.

Salerra Inc

Web: www.salerra.com, Email: [email protected]

Tel: 864-655-4552, Fax: 864-655-4558

Add: 20 Hampton Rd. Ste B, Lyman, SC 29365, USA

SALERRA Inc is a FDA registered pharmaceutical wholesaler with DEA

wholesale and export licenses of controlled substances. SALERRA Inc specializes

in supplying pharmaceutical products, reference listed drug, or comparator drugs

for clinical and non-clinical research use. SALERRA Inc has a global network of

suppliers and can offer research pharmaceuticals from international markets to

clients around the globe.

CALS Members

John ChiangHuiping Zhou

INNOVATIVE MODELS TO EMPOWER ANTIBODY DISCOVERYBiocytogen is a global biotech company that provides seamlessly integrated technologies for the

discovery and screening of antibody drug candidates. We provide top-notch services, technology

licenses, and co-development programs to transform the process how medicines are made.

RenMab™ Mouse:

• State-of-art chromosome engineering

• Complete humanization in the gene loci of variable

regions in heavy chain and kappa light chain genes

• Fully human antibody repertoire

• Intact immune response compared with wild type

mouse

www.biocytogen.com

[email protected]

BIOCYTOGEN

Gene editing service• CRISPR/Cas9-based Extreme Genome Editing (EGE™)

Animal model generation• Humanized immune-checkpoint mice, cre mouse/rat

models, immunodeficient B-NDG mice, humanized cytokine mice, humanized tumor cell lines

Preclinical services• In vivo study, in vitro assay, PK, PD, toxicity

Biocytogen provides research solution from Target to IND application.

800+Emoplyees worldwide

500+Drug evaluation projects delivered annually

1,700+ Global partners across academia and industry

Fully Human Antibody Mouse

Revolutionary Technology for

Antibody Discovery

Contact Biocytogen about partnership opportunities

DIO Diets (D12492 & D12451) MCD Diets (A02082002BR) CDAA Diets

CDAHFD (A06071302 & A06071309 ) GAN Diet (D09100310) CDHFD

ResearchDiets.com

Chinese Web WeChat

NASH/NAFLD Dietsfor Lab Animals

Ask Our Scientists about Custom NASH Diets for individual studies

NASH FibrosisSteatosisCholine Deficient + High Fat

High Saturated Fat

High Cholesterol

High Fructose

Hig

h Fa

t

Methionine & Choline Defi

cient

C

M

Y

CM

MY

CY

CMY

K

RDI _8.5 x 11_2020_CMYK AD_NASH CHINESE CALAS_FINAL.pdf 1 10/1/2020 3:50:57 PM

Junior Investigator Research Awardees

Shengmin YanTulane University School of MedicineMentor: Dr. Xiao-Ming Yin

Tian LanGuangdong Pharmaceutical UniversityMentor: Dr. Jiao Guo

Dong XiangTongji Hospital Affiliated with Tongji Medical College, Huazhong University of Science and TechnologyMentor: Dr. Dong Liu

Yun-Ling TaiVirginia Commonwealth UniversityMentor: Dr. Huiping Zhou

Postdoctoral Fellow Research Awardees

Seonghwan HwangNIAAA, NIHMentor: Dr. Bin Gao

Priyanka GhoshUniversity of Kansas Medical CenterMentor: Dr. Yuxia Zhang

Wei FanCedars-Sinai Medical CenterMentor: Dr. Shelly Lu

Liuying ChenTongji Medical College, Huazhong University of Science and TechnologyMentor: Dr. Yang Ling

Xiaoxiao JiangUniversity of Kansas Medical CenterMentor: Dr. Wen-Xing Ding

Konstantina KyritsiIndiana UniversityMentor: Drs. Heather Francis & Gianfranco Alpini

Dan LiNational Institutes of HealthMentor: Dr. Mitchell Ho

Tingting JiangUniversity of Massachusetts Medical SchoolMentor: Dr. Wen Xue


Wonhyo SeoNational Institutes on Alcohol Abuse and Alcoholism (NIAAA)Mentor: Dr. Bin Gao

Seol Hee ParkNational Institutes on Alcohol Abuse and Alcoholism (NIAAA)Mentor: Dr. Bin Gao

Lichun MaNational Cancer InstituteMentor: Dr. Xin Wei Wang

Robim M Rodrigues Laboratory of Liver Diseases, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health Mentor: Dr. Bin Gao


Xiaolin WangLaboratory of Liver Diseases, National Institute on Alcohol Abuse and Alcoholism, National Institutes of HealthMentor: Bin Gao

Junkai YanVirginia Commonwealth UniversityMentor: Huiping Zhou

Yanyan WangVirginia Commonwealth UniversityMentor: Huiping Zhou

Ming YangUniversity of MissouriMentor: Dr. Guangfu Li


Tianhao ZhouIndiana UniversityMentor: Drs. Gianfranco Alpini & Shannon Glaser

Jinfang ZhaoUnion Hospital, Tongji Medical CollegeHuazhong University of Science and TechnologyMentor: Ling Yang


Xiaojuan ChaoUniversity of Kansas Medical CenterMentor: Dr. Wen-Xing Ding

Graduate Student Research Awardees

Fan ShichengSchool of Pharmaceutical Sciences, Sun Yat-Sen UniversityMentor: Dr. Bi Huichang

Yaojie FuNational Institute on Alcohol Abuse and Alcoholism, National Institutes of HealthMentor: Dr. Bin Gao

Mengwei JiangUniversity of LouisvilleMentor: Dr. Wenke Feng

Xiaowen MaUniversity of Kansas Medical CenterMentor: Dr. Wen-Xing Ding

Daniel RizzoloRutgers UniversityMentor: Dr. Grace Guo

Vik MeadowsIndiana University School of MedicineMentor: Dr. Heather Francis

Mary F. StofanRutgers University Mentor: Dr. Grace L. Guo


Yilin YangYale UniversityMentor: Dr. Yasuko Iwakiri

Yang SunShandong University, Jinan Shandong, ChinaMentor: Dr. Chunhong Ma

Yuan ZhangVirginia Commonwealth UniversityMentor: Dr. Huiping Zhou


Past Keynote Speakers

John Y Chiang, Ph.D.Fellow of AASLDDistinguished University ProfessorNortheast Ohio Medical University

T. Jake Liang, MDNIH Distinguished InvestigatorChief: Liver Disease BranchFellow of the AAAS, AASLF, AGAMember of National Academy of Medicine

2019

2018

the 3rd cals annual symposium - scbasociety.org scba...gastroenterology, hepatology, nat...

Documents